• Home
Scientific article
OA Policy
English

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

ContributorsKossler, Thibaud; Alsina, M; Arnold, D; Ben-Aharon, I; Collienne, M; Lutz, M P; Neuzillet, C; Obermannova, R; Peeters, M; Sclafani, F; Smyth, E; Valle, J W; Wagner, A D; Wyrwicz, L; Fontana, E; Moehler, M
Published inESMO open, vol. 7, no. 2, 100392
Publication date2022-04
First online date2022-02-16
Abstract

There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

Keywords
  • Colorectal cancer
  • Neuroendocrine tumours
  • Oesophagus cancer
  • Pancreatic cancer
  • Stomach cancer
  • Gastrointestinal Neoplasms / drug therapy
  • Humans
  • Immunotherapy
  • Medical Oncology
Affiliation entities
Citation (ISO format)
KOSSLER, Thibaud et al. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective. In: ESMO open, 2022, vol. 7, n° 2, p. 100392. doi: 10.1016/j.esmoop.2022.100392
Main files (1)
Article (Published version)
accessLevelPublic CC BY-4.0
Identifiers
Commercial URLhttps://www.sciencedirect.com/science/article/pii/S2059702922000126
Journal ISSN2059-7029
62views
28downloads

Technical informations

Creation10/13/2022 9:38:45 AM
First validation05/23/2023 2:22:08 PM
Update time05/23/2023 2:22:08 PM
Status update05/23/2023 2:22:08 PM
Last indexation11/01/2024 5:08:54 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack